Last reviewed · How we verify
Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae
Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae is a Small molecule drug developed by Nanjing First Hospital, Nanjing Medical University. It is currently FDA-approved.
Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae, marketed by Nanjing First Hospital, Nanjing Medical University, is a combination therapy currently available in the market. The key composition patent expires in 2028, providing a strong barrier to generic competition until then. The primary risk is the lack of detailed clinical trial results and revenue data, which may limit investor confidence and market adoption.
At a glance
| Generic name | Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae |
|---|---|
| Sponsor | Nanjing First Hospital, Nanjing Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae CI brief — competitive landscape report
- Vonoprazan-Amoxicillin with Bifidobacterium tetravaccae updates RSS · CI watch RSS
- Nanjing First Hospital, Nanjing Medical University portfolio CI